Myelo Therapeutics GmbH   Report issue

For profit Phase 2
Founded: Berlin Germany (2013)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2016
NCT02692742
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now